SAN DIEGO, July 21, 2017 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused
on neurological and endocrine related disorders, announced that
Julie Cooke is joining as Chief
People Officer in September 2017 and
will be a member of the Management Committee.
"Neurocrine is delighted to welcome Julie Cooke as our
Chief People Officer to lead our Human Resource function,"
said David-Alexandre C. Gros, President and Chief Operating
Officer of Neurocrine Biosciences. "Julie's deep and broad
experience across all aspects of human resources will be
tremendously valuable as we grow and continue to expand our
capabilities while remaining true to the culture that has
underpinned our success."
"Neurocrine is a remarkably patient focused, innovative and
culture driven company," said Ms. Cooke. "I am very excited to join
the company during this pivotal growth phase."
Julie Cooke comes to Neurocrine
from the Sanford Burnham Prebys Medical Research Institute where
she served as Senior Vice President for Human Resources and was a
member of the executive management team. Previously, Ms. Cooke
held multiple positions at the Vice President level at Life
Technologies, including being the human resource partner to the
Chief Operating Officer, Division Presidents and Global Function
Leads. Prior to Life Technologies, she ran human resources and
was a member of the executive management team at SGX
Pharmaceuticals. Ms. Cooke began her career at PepsiCo, The
Pepsi Bottling Group, and Gateway, where she held positions of
increasing responsibility in human resources. She holds a
Bachelor of Arts in Economics from Colorado
College.
About Neurocrine Biosciences
Neurocrine Biosciences is a San
Diego based biotechnology company focused on neurologic,
psychiatric and endocrine related disorders. In April of 2017, the
FDA approved INGREZZA® (valbenazine) capsules for the treatment of
adults with tardive dyskinesia (TD). INGREZZA is a novel,
selective vesicular monoamine transporter 2 (VMAT2) inhibitor, and
is the first and only FDA-approved product indicated for the
treatment of adults with TD. The Company markets INGREZZA in
the United States. The Company's
three late-stage clinical programs are: elagolix, a
gonadotropin-releasing hormone antagonist for women's health that
is partnered with AbbVie Inc.; opicapone, a novel, once-daily,
peripherally-acting, highly-selective catechol-o-methyltransferase
inhibitor under investigation as adjunct therapy to levodopa in
Parkinson's patients; and INGREZZA (valbenazine), a novel,
once-daily, selective VMAT2 inhibitor under investigation for the
treatment of Tourette syndrome.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
Forward Looking Statements
In addition to historical facts, this press release contains
forward-looking statements that involve a number of risks and
uncertainties. These statements include, but are not limited to,
statements related to the Company's ability to successfully
grow. Among the factors that could cause actual results to
differ materially from those indicated in the forward-looking
statements are: risks and uncertainties associated with
Neurocrine's business and finances in general, as well as risks and
uncertainties associated with the commercialization of INGREZZA and
the development of the Company's product candidates; and other
risks described in the Company's periodic reports filed with the
Securities and Exchange Commission, including without limitation
the Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2017. The Company disclaims
any obligation to update the statements contained in this press
release after the date hereof.
View original
content:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-the-appointment-of-julie-cooke-as-chief-people-officer-300492091.html
SOURCE Neurocrine Biosciences, Inc.